Is Liraglutide compatible with breastfeeding? Do we have alternatives for Liraglutide?

Liraglutide

August 20, 2017 (Low Risk)

Glucagon-like peptide 1 analogue that stimulates endogenous insulin secretion.
Used to treat obesity and type 2 diabetes in combination with other oral antidiabetics, especially metformin.
Administered subcutaneously.
The most common side effects are nausea, vomiting and diarrhea. Low risk of hypoglycemia in monotherapy.

Since the last update we have not found published data on its excretion in breast milk.

Its pharmacokinetic data (high molecular weight and high percentage of plasma protein binding) make it very unlikely that significant amounts will pass into breast milk (Serrano 2014).

Due to its protein nature, it deteriorates in the gastrointestinal tract, not being absorbed (Serrano 2014). This low oral bioavailability would make it difficult for it to pass to the infant’s plasma ingesting breast milk, except in preterm infants and in the immediate neonatal period when there may be increased intestinal permeability.

Diet, exercise, and breastfeeding improve blood sugar levels.


See below the information of this related product:

Alternatives

Very Low Risk

Compatible. Not risky for breastfeeding or infant.

Low Risk

Moderately safe. Mild risk possible. Follow up recommended. Read the Comment.

High Risk

Poorly safe. Evaluate carefully. Use a safer alternative. Read the Comment.

Very High Risk

Not recommended. Cessation of breastfeeding or alternative.

Writings

  • ليراغلوتيد (Arabic)
  • Лираглутид (Cyrillic)
  • 利拉糖肽 (Chinese)
  • リラグルチド (Japanese)
  • C172H265N43O51 (Molecular formula)
  • NN-2211 (Experimental code/s)

References

  1. EMA. Liraglutide. Drug Summary. 2016 Full text (in our servers)
  2. EMA. Liraglutida. Ficha técnica. 2016 Full text (in our servers)
  3. Serrano Aguayo P, García de Quirós Muñoz JM, Bretón Lesmes I, Cózar León MV. Tratamiento de enfermedades endocrinológicas durante la lactancia. [Endocrinologic diseases management during breastfeeding.] Med Clin (Barc). 2015Abstract